Skip to main content Back to Top
Advertisement

8/7/2019

Methocarbamol Tablets

Products Affected - Description

    • Robaxin oral tablet, Endo Pharmaceuticals, 500 mg, bottle, 100 count, NDC 52244-0429-10 - discontinued
    • Robaxin oral tablet, Endo Pharmaceuticals, 750 mg, bottle, 100 count, NDC 52244-0449-10
    • Methocarbamol oral tablet, Camber, 500 mg, bottle, 100 count, NDC 31722-0533-01
    • Methocarbamol oral tablet, Camber, 500 mg, bottle, 500 count, NDC 31722-0533-05
    • Methocarbamol oral tablet, Camber, 750 mg, bottle, 100 count, NDC 31722-0534-01
    • Methocarbamol oral tablet, Camber, 750 mg, bottle, 500 count, NDC 31722-0534-05
    • Methocarbamol oral tablet, Par Pharmaceuticals, 500 mg, bottle, 100 count, NDC 00603-4485-21 - discontinued
    • Methocarbamol oral tablet, Par Pharmaceuticals, 500 mg, bottle, 500 count, NDC 00603-4485-28 - discontinued
    • Methocarbamol oral tablet, Par Pharmaceuticals, 750 mg, bottle, 100 count, NDC 00603-4486-21 - discontinued
    • Methocarbamol oral tablet, Par Pharmaceuticals, 750 mg, bottle, 500 count, NDC 00603-4486-28 - discontinued
    • Methocarbamol oral tablet, Par Pharmaceuticals, 750 mg, bottle, 1000 count, NDC 00603-4486-32 - discontinued
    • Methocarbamol oral tablet, Solco Healthcare US, 500 mg, bottle, 500 count, NDC 43547-0405-50
    • Methocarbamol oral tablet, Virtus, 500 mg, bottle, 100 count, NDC 69543-0134-10 - discontinued
    • Methocarbamol oral tablet, Virtus, 500 mg, bottle, 500 count, NDC 69543-0134-50 - discontinued
    • Methocarbamol oral tablet, Virtus, 750 mg, bottle, 100 count, NDC 69543-0135-10 - discontinued
    • Methocarbamol oral tablet, Virtus, 750 mg, bottle, 500 count, NDC 69543-0135-50 - discontinued

Reason for the Shortage

    • Bayshore states the shortage is due to increased demand.
    • Camber states the shortage is due to an API shortage.
    • Endo did not provide a reason for the shortage.
    • Hikma is not actively marketing methocarbamol tablets.
    • Par discontinued methocarbamol tablets in July 2018.
    • Solco states the shortage is due to an API shortage.
    • Virtus discontinued methocarbamol tablets in June 2019.

Available Products

    • Methocarbamol oral tablet, Bayshore, 500 mg, bottle, 100 count, NDC 76385-0123-01
    • Methocarbamol oral tablet, Bayshore, 500 mg, bottle, 500 count, NDC 76385-0123-50
    • Methocarbamol oral tablet, Bayshore, 750 mg, bottle, 100 count, NDC 76385-0124-01
    • Methocarbamol oral tablet, Bayshore, 750 mg, bottle, 500 count, NDC 76385-0124-50
    • Methocarbamol oral tablet, Solco Healthcare US, 500 mg, bottle, 100 count, NDC 43547-0405-10
    • Methocarbamol oral tablet, Solco Healthcare US, 750 mg, bottle, 100 count, NDC 43547-0226-10
    • Methocarbamol oral tablet, Solco Healthcare US, 750 mg, bottle, 500 count, NDC 43547-0226-50

Estimated Resupply Dates

    • Camber has all methocarbamol tablets available for contracted customers. All presentations are on allocation for non-contracted customers.
    • Solco has methocarbamol 500 mg tablets in 500 count on back order and the company cannot estimate a release date.
    • Endo has Robaxin 750 mg tablets in 100 count on back order and the company cannot estimate a release date.

Updated

Updated August 7, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created May 8, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins